ストックスクリーナーアプリを入手
12.28
3.08%
-0.39
プレマーケット:
11.91
-0.37
-3.01%
Aardvark Therapeutics Inc (AARD) 最新ニュース
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Aardvark Therapeutics announces leadership appointments - marketscreener.com
Aardvark Therapeutics Launches Dermatology Unit, Names Bryan Jones as Ardia CEO - marketscreener.com
Aardvark Therapeutics, Inc. Announces Appointment of Executive, Effective February 9, 2026 - marketscreener.com
Aardvark Therapeutics Establishes Ardia Subsidiary To Advance Dermatology Pipeline - Nasdaq
Aardvark Therapeutics Appoints Derrick Li as Chief Business Officer; Gives CFO Nelson Sun Additional Role of COO - marketscreener.com
Aardvark Launches Ardia Dermatology Unit, Realigns Leadership - TipRanks
Aardvark Therapeutics Announces Leadership Appointments - Bitget
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer - The Manila Times
Aardvark creates Ardia to develop psoriasis and severe skin treatments - Stock Titan
Aardvark Therapeutics' (AARD) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Aardvark Expands PWS Phase 3 Trial to Younger Children - TipRanks
Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility - TradingView
Aardvark Therapeutics Announces FDA Submission and IRB - GlobeNewswire
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Undervalued Obesity Innovator: Justifying a Buy on Aardvark’s Dual Rare-Disease and Mainstream Metabolic Opportunity - TipRanks
HC Wainwright Reiterates "Buy" Rating for Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) Trading 12% HigherTime to Buy? - MarketBeat
Insider Stock Buying Reaches US$875.0k On Aardvark Therapeutics - 富途牛牛
B.Riley initiates coverage on Aardvark Therapeutics stock with Buy rating - Investing.com Nigeria
Smart Money: Does Aardvark Therapeutics Inc have declining or rising EPSCPI Data & Low Risk Investment Opportunities - baoquankhu1.vn
Ten new option listings and two option delistings on January 22nd - TipRanks
Aardvark Therapeutics: Clinical Momentum and 2026 Catalyst Stack Underpin Buy Rating and $26 Target - TipRanks
Market Outlook: Can Aardvark Therapeutics Inc expand its profit marginsJuly 2025 Action & Growth Oriented Trade Recommendations - baoquankhu1.vn
Aardvark Therapeutics, Inc. (NASDAQ:AARD) stock most popular amongst retail investors who own 32%, while private equity firms hold 28% - Yahoo Finance
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% Higher – Time to Buy? - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% HigherTime to Buy? - MarketBeat
Treasury Yields: How Aardvark Therapeutics Inc stock compares to growth peersJuly 2025 Summary & Long-Term Capital Growth Ideas - Bộ Nội Vụ
RSI Check: Can Aardvark Therapeutics Inc stock rebound after recent weaknessMarket Activity Summary & High Conviction Buy Zone Alerts - Bộ Nội Vụ
Aardvark Therapeutics updates investor presentation on hunger therapies - TipRanks
Aardvark Therapeutics, Inc Updates Corporate Presentation - TradingView — Track All Markets
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target - Investing.com
What risks investors should watch in Aardvark Therapeutics Inc. stockBull Run & Safe Capital Growth Tips - ulpravda.ru
Can Aardvark Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Spike Watch & Comprehensive Market Scan Insights - Улправда
Will Aardvark Therapeutics Inc. stock deliver consistent dividendsPortfolio Return Report & AI Powered Buy/Sell Recommendations - Улправда
Fed Watch: How Aardvark Therapeutics Inc. stock trades during market volatility2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - Улправда
Nasdaq Moves: How Aardvark Therapeutics Inc. stock trades during market volatilityQuarterly Portfolio Summary & Technical Buy Zone Confirmation - Улправда
What AI ML Trends Might Elevate Advance Metering Technology Limiteds Stock ProspectsLong-Term Growth Stocks & Free Unstoppable Trading Performance - earlytimes.in
Aug Gainers: Will Aardvark Therapeutics Inc stock deliver consistent dividends2025 Momentum Check & Community Trade Idea Sharing Platform - moha.gov.vn
Aardvark Therapeutics up 9% at $10.10 after Raymond James Strong Buy initiation - MSN
Aardvark Therapeutics prices $94M IPO at $16 per share - MSN
Critical Contrast: Aardvark Therapeutics (AARD) and The Competition - Defense World
Aardvark Therapeutics (AARD) – Investment Analysts’ Recent Ratings Updates - Defense World
Aardvark Therapeutics initiated with an outperform at Oppenheimer - MSN
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating - Investing.com India
Oppenheimer Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):